AccessibilityHelp

Most Active Stocks Daily Stock Gainers Daily Stock Losers

Most Active Stocks Daily Stock Gainers Daily Stock Losers

Maxx Chatsko

XMFBlacknGoldX

Maxx has been a contributor to Fool.com since 2013. He graduated from the State University of New York College of Environmental Science and Forestry (2012) with a Bachelor of Science in Bioprocess Engineering and from Carnegie Mellon University (2016) with a Master of Science in Materials Science & Engineering.

Articles by Maxx Chatsko — Page 127

Will Investors Take the Plunge Over the Patent Cliff With Humira?

May 13, 2013 by Maxx Chatsko

Will Investors Take the Plunge Over the Patent Cliff With Humira?

Humira, the world's most successful current drug, is set to lose exclusivity in 2016 in the U.S. and in 2018 in Europe. The biologic provides over half of AbbVie's total revenue. Should investors start to panic?

GevoPlant_Luverne

May 11, 2013 by Maxx Chatsko

This Bill Wants to Cut Ethanol Production in Half

Recently proposed legislation aims to cut biofuels requirements by almost half. The bill itself is not perfect, but it is a big step to correcting the flawed Renewable Fuel Standard.

Solazyme Adds (More) Precision to Tailored Oil Platform

May 9, 2013 by Maxx Chatsko

Solazyme Adds (More) Precision to Tailored Oil Platform

What investors need to know about the first quarter developments of Solazyme.

This Biotech Stock Keeps Investors Patiently Waiting

May 8, 2013 by Maxx Chatsko

This Biotech Stock Keeps Investors Patiently Waiting

What investors need to know about first-quarter earnings from Codexis.

3 Hallmarks of a Megablockbuster

May 7, 2013 by Maxx Chatsko

3 Hallmarks of a Megablockbuster

Everyone loves a drug with blockbuster potential. But why stop there? Here's a quick guide on how to find a megablockbuster, courtesy of three wildly successful drugs.

Is the Biggest Pharma Company in the World the Best Investment?

May 7, 2013 by Maxx Chatsko

Is the Biggest Pharma Company in the World the Best Investment?

Being the world's largest pharmaceutical company has its perks, but does it make Pfizer the best investment?

REG Earnings Get a Boost From Fuel Credits

May 2, 2013 by Maxx Chatsko

REG Earnings Get a Boost From Fuel Credits

The latest earnings from Renewable Energy Group are the best for any first quarter in the company's history.

Don't Try to Pick the Best Biotech Company

Apr 29, 2013 by Maxx Chatsko

Don't Try to Pick the Best Biotech Company

History suggests that picking favorites during pharmaceutical run-ups can leave you with sub-optimal returns. When it comes to choosing between a basket of stocks your best bet is to own them all.

3 Biotech Companies for Young Investors

Apr 29, 2013 by Maxx Chatsko

3 Biotech Companies for Young Investors

Investing in biotech can lead to some phenomenal returns over the long term. Investing when you're young can do the same. Let's mash the two together.

1 Fertilizer Stock to Buy When Natural Gas Prices Rise

Apr 29, 2013 by Maxx Chatsko

1 Fertilizer Stock to Buy When Natural Gas Prices Rise

Here's one fertilizer company that doesn't fear rising natural gas prices.

AGM_battery_production_hires

Apr 23, 2013 by Maxx Chatsko

Can Johnson Controls Stock Shake off European Worries?

Industrial conglomerates haven't had much luck in Europe recently. It is certainly affecting Johnson Controls, but it may not be the most important factor for investors.

Is Southern Company Stock Too Hot to Touch?

Apr 22, 2013 by Maxx Chatsko

Is Southern Company Stock Too Hot to Touch?

Southern has blazed trails to new all-time highs. Should investors ignore the climb or remain cautious about current prices?

Will Natural Gas Prices Tank Consolidated Edison Stock?

Apr 22, 2013 by Maxx Chatsko

Will Natural Gas Prices Tank Consolidated Edison Stock?

Natural gas futures contracts are trading at well over double last year's prices. That threatens an important profitability metric for ConEd, which means its stock could be doomed.

Yawn Your Way to Retirement With Abbott Laboratories Stock

Apr 22, 2013 by Maxx Chatsko

Yawn Your Way to Retirement With Abbott Laboratories Stock

Medical devices, lab instruments, and nutritionals may only conjure up a yawn from most investors. Who said that's a bad thing?

PineBeetleKillwood

Apr 20, 2013 by Maxx Chatsko

Ferocious Beetles Destroy Forests and Hurt Homebuilders

Timber prices have reached prices last seen during the housing bubble, but supply and demand are far below those historical levels. What gives?

Are These 4 Stocks Still Cheap Investments?

Apr 18, 2013 by Maxx Chatsko

Are These 4 Stocks Still Cheap Investments?

These stocks have risen sharply in the past few months. Are they still cheap investments?

Is Amgen Stock Too Hot to Touch?

Apr 18, 2013 by Maxx Chatsko

Is Amgen Stock Too Hot to Touch?

Shares of this Big Pharma member are flaming hot. Should you stay away or bust out the oven mitts?

Merck Stock Isn't Worth It

Apr 18, 2013 by Maxx Chatsko

Merck Stock Isn't Worth It

The patent cliff will spare no member of big pharma when all is said and done. Unfortunately, Merck ranks near the bottom of the pack in terms of emergency preparedness.

This Blow to Malaria Is No News for Investors

Apr 15, 2013 by Maxx Chatsko

This Blow to Malaria Is No News for Investors

The company's process produces nearly 16 times more artemisinic acid, an intermediate to the most potent malaria drug, than previous methods. That is tremendous news for patients, terrible news for malaria, and no news for investors.

Will the FDA Wake Up to This Drug's Potential?

Apr 8, 2013 by Maxx Chatsko

Will the FDA Wake Up to This Drug's Potential?

This promising, next-generation drug has encountered a series of delays since 2008. Can it finally gain approval in 2013 on its way to blockbuster potential?

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services